Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.
Yamamoto Y, Välitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM. Yamamoto Y, et al. Among authors: krauwinkel w. CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):765-777. doi: 10.1002/psp4.12250. Epub 2017 Oct 13. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28891201 Free PMC article.
A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.
Yamamoto Y, Välitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC. Yamamoto Y, et al. Among authors: krauwinkel w. Pharm Res. 2017 Feb;34(2):333-351. doi: 10.1007/s11095-016-2065-3. Epub 2016 Nov 18. Pharm Res. 2017. PMID: 27864744 Free PMC article.
The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model.
Duong JK, de Winter W, Choy S, Plock N, Naik H, Krauwinkel W, Visser SA, Verhamme KM, Sturkenboom MC, Stricker BH, Danhof M. Duong JK, et al. Among authors: krauwinkel w. Br J Clin Pharmacol. 2017 Mar;83(3):487-497. doi: 10.1111/bcp.13144. Epub 2016 Nov 17. Br J Clin Pharmacol. 2017. PMID: 27679422 Free PMC article.
Specific pharmacokinetic aspects of the urinary tract.
Korstanje C, Krauwinkel W. Korstanje C, et al. Among authors: krauwinkel w. Handb Exp Pharmacol. 2011;(202):267-82. doi: 10.1007/978-3-642-16499-6_13. Handb Exp Pharmacol. 2011. PMID: 21290231 Review.
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Dickinson J, et al. Among authors: krauwinkel w. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3. Clin Drug Investig. 2013. PMID: 23208320 Clinical Trial.
An example of optimal phase II design for exposure response modelling.
Maloney A, Schaddelee M, Freijer J, Krauwinkel W, van Gelderen M, Jacqmin P, Simonsson US. Maloney A, et al. Among authors: krauwinkel w. J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):475-91. doi: 10.1007/s10928-010-9168-y. Epub 2010 Sep 25. J Pharmacokinet Pharmacodyn. 2010. PMID: 20872056
48 results